Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Benitec Biopharma Inc. (BNTC)

Benitec Biopharma Names Ernst & Young as New Independent Auditor for Fiscal 2027

Neutral Impact 2 of 5 other Written later

Benitec Biopharma disclosed that Ernst & Young LLP (EY) has been engaged as its independent registered public accounting firm for the fiscal year ending June 30, 2027, after EY completed its client acceptance procedures on September 28, 2026. The company and EY signed an engagement letter on September 29, 2026. The filing is an administrative update on the company's auditor and does not report financial results or a disagreement with the prior accountant.

Key points

  • EY completed client acceptance procedures on September 28, 2026.
  • The Company and EY executed an engagement letter on September 29, 2026.
  • EY is engaged for the fiscal year ending June 30, 2027.
  • The engagement was first reported in a Form 8-K filed September 24, 2026.

The filing

CompanyBenitec Biopharma Inc. (BNTC)
Form8-K, current report
Filed with the SECSep 30, 2026, 4:08 PM ET
Accession number0001193125-26-409052

Items reported: 4.01 Auditor Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.